Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 04/13/18 → 04/13/23 |
Funding
- Boehringer Ingelheim Pharmaceutical: $104,608.79
A phase II randomised, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 425809 once daily over 12 week treatment period in patients with Schizophrenia
- Dubovsky, Steven (PI)
- Anker, Jeffrey (CoI)
Project: Research